drugset / Trial / NCT06350955
IV Iron-induced Hypophosphatemia After RYGB
RandomizedParallel-groupSingle-blindTreatment
Summary
The primary objective of the study is to compare the incidence of hypophosphatemia in RYGB patients treated with intravenous (IV) single dose of iron isomaltoside (Monofer®) or ferric carboxymaltose (Ferinject®).
Timeline
- Start
- 2024-05-02
- Primary completion
- 2026-06
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ferric carboxymaltose | Other / unclassified | 500 mg | Intravenous |
| Subject | Iron isomaltoside 1000 | Unknown | 500 mg | Intravenous |